Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.
Department of Laboratory Medicine, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, China.
J Clin Lab Anal. 2021 Nov;35(11):e24059. doi: 10.1002/jcla.24059. Epub 2021 Oct 15.
The six sigma model has been widely used in clinical laboratory quality management. In this study, we first applied the six sigma model to (a) evaluate the analytical performance of urinary biochemical analytes across five laboratories, (b) design risk-based statistical quality control (SQC) strategies, and (c) formulate improvement measures for each of the analytes when needed.
Internal quality control (IQC) and external quality assessment (EQA) data for urinary biochemical analytes were collected from five laboratories, and the sigma value of each analyte was calculated based on coefficients of variation, bias, and total allowable error (TEa). Normalized sigma method decision charts for these urinary biochemical analytes were then generated. Risk-based SQC strategies and improvement measures were formulated for each laboratory according to the flowchart of Westgard sigma rules, including run sizes and the quality goal index (QGI).
Sigma values of urinary biochemical analytes were significantly different at different quality control levels. Although identical detection platforms with matching reagents were used, differences in these analytes were also observed between laboratories. Risk-based SQC strategies for urinary biochemical analytes were formulated based on the flowchart of Westgard sigma rules, including run size and analytical performance. Appropriate improvement measures were implemented for urinary biochemical analytes with analytical performance lower than six sigma according to the QGI calculation.
In multilocation laboratory systems, a six sigma model is an excellent quality management tool and can quantitatively evaluate analytical performance and guide risk-based SQC strategy development and improvement measure implementation.
六西格玛模型已广泛应用于临床实验室质量管理。本研究首次将六西格玛模型应用于(a)评估五个实验室的尿生化分析物的分析性能,(b)设计基于风险的统计质量控制(SQC)策略,以及(c)在需要时为每个分析物制定改进措施。
从五个实验室收集尿生化分析物的内部质量控制(IQC)和外部质量评估(EQA)数据,并根据变异系数、偏倚和总允许误差(TEa)计算每个分析物的西格玛值。然后为这些尿生化分析物生成标准化西格玛方法决策图。根据 Westgard 西格玛规则的流程图,为每个实验室制定基于风险的 SQC 策略和改进措施,包括运行规模和质量目标指数(QGI)。
不同质量控制水平的尿生化分析物的西格玛值有显著差异。尽管使用了相同的检测平台和匹配的试剂,但实验室之间这些分析物也存在差异。根据 Westgard 西格玛规则的流程图,为尿生化分析物制定了基于风险的 SQC 策略,包括运行规模和分析性能。根据 QGI 计算,对分析性能低于六西格玛的尿生化分析物实施了适当的改进措施。
在多地点实验室系统中,六西格玛模型是一种优秀的质量管理工具,可以定量评估分析性能,并指导基于风险的 SQC 策略制定和改进措施的实施。